[HTML][HTML] Understanding the determinants of BnAb induction in acute HCV infection

AP Underwood, MR Walker, NA Brasher, AA Eltahla… - Viruses, 2018 - mdpi.com
AP Underwood, MR Walker, NA Brasher, AA Eltahla, L Maher, F Luciani, AR Lloyd, RA Bull
Viruses, 2018mdpi.com
Despite recent advances in curative therapy, hepatitis C virus (HCV) still remains a global
threat. In order to achieve global elimination, a prophylactic vaccine should be considered
high priority. Previous immunogens used to induce broad neutralising antibodies (BnAbs)
have been met with limited success. To improve immunogen design, factors associated with
the early development of BnAbs in natural infection must first be understood. In this study, 43
subjects identified with acute HCV were analysed longitudinally using a panel of …
Despite recent advances in curative therapy, hepatitis C virus (HCV) still remains a global threat. In order to achieve global elimination, a prophylactic vaccine should be considered high priority. Previous immunogens used to induce broad neutralising antibodies (BnAbs) have been met with limited success. To improve immunogen design, factors associated with the early development of BnAbs in natural infection must first be understood. In this study, 43 subjects identified with acute HCV were analysed longitudinally using a panel of heterogeneous HCV pseudoparticles (HCVpp), to understand the emergence of BnAbs. Compared to those infected with a single genotype, early BnAb development was associated with subjects co-infected with at least 2 HCV subtypes during acute infection. In those that were mono-infected, BnAbs were seen to emerge with increasing viral persistence. If subjects acquired a secondary infection, nAb breadth was seen to boost upon viral re-exposure. Importantly, this data highlights the potential for multivalent and prime-boost vaccine strategies to induce BnAbs against HCV in humans. However, the data also indicate that the infecting genotype may influence the development of BnAbs. Therefore, the choice of antigen will need to be carefully considered in future vaccine trials.
MDPI